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Simple Summary: Pancreatic ductal adenocarcinoma (PDAC) is one of the tumors with the highest
mortality, for which survival has hardly changed in the last 40 years. This high mortality is due to
the lack of tests that would allow an early diagnosis and the fact that current treatments are not very
effective. Liquid biopsy (LB) represents an interesting tool that can help in early diagnosis, treatment
selection, disease monitoring, evaluation of the response and prognosis. It is a minimally invasive
and risk-free procedure that can detect both the presence of genetic material from the tumor and
circulating tumor cells (CTCs) in the blood and in other bodily fluids, and therefore distantly reflect
the global status of the disease.
Abstract: Pancreatic ductal adenocarcinoma (PDAC) exhibits the poorest prognosis of all solid
tumors, with a 5-year survival of less than 10%. To improve the prognosis, it is necessary to advance
in the development of tools that help us in the early diagnosis, treatment selection, disease monitoring,
evaluation of the response and prognosis. Liquid biopsy (LB), in its different modalities, represents a
particularly interesting tool for these purposes, since it is a minimally invasive and risk-free procedure
that can detect both the presence of genetic material from the tumor and circulating tumor cells
(CTCs) in the blood and therefore distantly reflect the global status of the disease. In this work
we review the current status of the main LB modalities (ctDNA, exosomes, CTCs and cfRNAs) for
detecting and monitoring PDAC.
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1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents the fourth leading cause of
death from cancer in the world, with a 5-year survival of less than 10% [1,2]. In fact, unlike
what happens with other tumors, its mortality has not been reduced in the last decades.
Diverse estimates, based on the analysis of cases of the last 10 years, foresee an annual
increase of 0.8% in its diagnosis, therefore, if there are no important advances, by 2030 it
will represent the second cause of death from cancer in the United States and the EU, only
below lung cancer [3–5].
Some of the factors that contribute to this high mortality are its insidious onset, with
unspecific symptoms, and the lack of diagnostic tests and biomarkers that are sensitive and
specific enough to allow its early detection. All this means that by the time of diagnosis
80% of tumors are already in incurable stages (locally advanced or metastatic). On the
other hand, in patients with apparently localized disease, surgery is the only potentially
curative treatment, but despite radical resection (R0), 80% of patients will present local or
distant relapses after surgery [5].
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To improve the current results of surgery, the therapeutic guidelines recommend ad-
ministering adjuvant chemotherapy treatment for 6 months with the modified 5-fluorouracil-
leucovorin-irinotecan-oxaliplatin (mFOLFIRINOX) regimen [6]. With this scheme, a me-
dian overall survival (OS) of 54.4 months and a median disease-free survival (DFS) of 21.6
months have been reported. However, this treatment can cause a high rate of grade 3–4
adverse events (affecting 76% of patients) [7]. This has led the guidelines to recommend
its administration to patients with ECOG PS 0–1, leaving the combination of gemcitabine-
capecitabine for patients with ECOG PS 2 [6]. On the other hand, despite the improvement
that adjuvant treatment with mFOLFIRINOX supposes, 60% of the patients will still relapse
after 3 years [7]. Therefore, to avoid exposure to unnecessary toxicity and optimize the
efficacy of adjuvant treatment, it would be necessary to identify the patients who are really
going to benefit from adjuvant treatment.
Neoadjuvant treatments (induction chemotherapy and/or chemoradiotherapy) fol-
lowed by surgery are common for borderline-resectable PDAC and are under investigation
in initially resectable disease. The results obtained suggest that this strategy facilitates
complete resection (resectability), increases the probability of achieving negative resec-
tion margins, and improves OS [8–11]. In this context, the monitoring of the response
to treatment is particularly relevant in order to determine the response of the tumor to
preoperative treatment and therefore the resectability. However, various authors have
pointed out that the radiological images, TC or MRI, obtained after neoadjuvant therapy
do not predict with certainty the resectability of the tumor [11], so it is necessary to have
more reliable methods of evaluation.
The standard of care for patients with locally advanced and metastatic PDAC is
chemotherapy. Radiotherapy could be an option in locally advanced PDACs in which
induction chemotherapy achieves control of the disease. Despite new chemotherapy regi-
mens developed during the last years (FOLFIRINOX and gemcitabine plus nab-paclitaxel),
the median OS continues under 12 months [12,13]. On the other hand, we do not have
effective targeted therapies for most of the driver mutations detected in PDAC, although it
has been reported that BRCA1/2 mutations identify a small group of patients who benefit
from platinum-based chemotherapy and PARP-inhibitors [14]. Likewise, the presence
of microsatellites and NTRK gene fusions predict the response to immune checkpoints
inhibitors [15] and tyrosine-kinase inhibitors [16], although the survival improvement is
not as successful as the observed in other tumors. Despite all this advances, OS in PDAC
has hardly improved in the last decades.
To improve the prognosis of patients with PDAC, it is essential to develop new treat-
ments, but other strategies are also of interest, such as the identification of biomarkers that
allow the personalization of treatments and help in early diagnosis, predict its recurrence
and monitor the response to treatment and the evolution of the disease. Liquid biopsy
(LB), in its different modalities, represents a particularly interesting tool for these purposes,
since it is a minimally invasive and risk-free procedure that can detect both the presence of
genetic material from the tumor and circulating tumor cells (CTCs) in the blood and other
body fluids and therefore distantly reflect the global status of the disease [17,18].
An additional advantage of LB is that it avoids the traditional difficulty of obtaining
a tumor sample in patients with advanced PDAC for molecular studies. In healthcare
practice, the tumor sample is obtained using endoscopic-ultrasound guided fine-needle
aspiration (US-FNA), which achieves a limited number of cells that, although sufficient for
cytological diagnosis, often are not enough for molecular studies [19]. Furthermore, LB
allows longitudinal monitoring of the molecular profile of the tumor during its evolution
(Figure 1).
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Recent technological and molecular advances have increased our ability to detect
and analyze LB components. In the following lines we will briefly introduce the different
methods currently available for blood-based LBs (Table 1).
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Table 1. Methods for isolation and analysis of liquid biopsy components in pancreatic cancer. Overview of the advantages
and disadvantages of the described methods.
LB Component Technique Advantages Disadvantages Ref.
cfDNA
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Affinity-based isolation High purity and specificity Low sample yield
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Higher sensitivity & accuracy
Lower sample volume required
More reproducible than qPCR
Tedious assay
optimization
LB: liquid biopsy; qPCR: real-time quantitative-PCR; dPCR: digital-PCR; ddPCR: droplet-dPCR, NGS: next generation sequencing; RT-qPCR:
quantitative reverse transcription PCR; WGS: whole genome sequencing; WES: whole exome sequencing. * Most used/gold standard.
2.1. Cell Free DNA (cfDNA)
In cancer patients, cfDNA is released by tumor cells through apoptosis, necrosis,
or active release. This DNA is called circulating tumor DNA (ctDNA) and it contains
mutations that are specific to cancer cells [21]. cfDNA can be isolated from plasma or
serum, but plasma is preferred to avoid possible contamination of serum with white blood
cells during the clotting process [24].
ctDNA sequencing techniques need to be very sensitive and specific to overcome the
low concentration of ctDNA in early stages of disease and the presence of cfDNA from
normal cells that can result in false positives [23].
PCR-based sequencing methods are very sensitive, but they can only detect known
variants. The most commonly used methods are real-time quantitative PCR (qPCR), which
is fast and inexpensive but it can only detect mutant allele fractions (MAF) over 10%,
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and digital PCR (dPCR), an ultrasensitive detection method that separates the sample
into thousands of parallel PCR reactions to reduce background noise and it can detect
MAF inferior to 0.1% [23]. Droplet-dPCR (ddPCR) and BEAMing are the current standard
approaches used for mutation detection in cfDNA with sensitivities between 0.01–0.1% [25].
Next-generation sequencing (NGS)-based methods permit high throughput analysis,
can screen for unknown variants and can also identify structural variants and copy number
variations, but with a lower sensitivity (approximately 1%) than dPCR. Platforms such
as safe-sequencing system (Safe-SeqS) [26], Tagged-Amplicon deep sequencing (TAm-
Seq) [27], Ion-AmpliSeq [28], CAncer Personalized Profiling by deep sequencing (CAPP-
Seq) [29], and sensitive mutation detection using sequencing (SiMSen-seq) [30] have been
developed. Recent advances have also enabled whole-genome sequencing in LB [23,24].
CtDNA methylation analysis has been used to evaluate cancer risk and monitor
disease progression and metastasis. CtDNA methylation pattern is tissue and cell specific,
and the information provided by these analyses can help determining the primary location
of the tumor with high specificity and sensitivity [52,53]. Methylation-specific PCR [54]
and MethyLight [55] platform have been used for this purpose and show a high sensitivity
in the detection of these variants.
2.2. Exosomes
Exosomes are extracellular vesicles of endosomal origin secreted by all cell types that
can be found in most body fluids. Their cargo material includes proteins, lipids, metabolites
and nucleic acids (DNA and RNAs), and tumor derived exosomes (TDEs) contain specific
surface proteins and other cellular contents that reflect the tumor cell of origin [22,56].
Methods for isolating exosomes can be density-based, size-based or affinity-based.
Density-based separation is the most commonly used, and includes centrifugation or
ultracentrifugation protocols that are time consuming, and the high speed of centrifugation
might damage the exosomes and release contaminating proteins [20]. Size-based methods
include size exclusion chromatography (SEC), a column-based technology that renders a
purified exosomal fraction [31], filtration protocols with membranes of nanometer pore
sizes, and microfluidic devices that use electrophoresis [32–34]. Both density and size-
based methods result in contaminated products with low specificity and concentration
of exosomes and cannot isolate TDEs. Affinity-based methods can isolate exosomes with
higher purity and specificity, but result in a low sample yield. These approaches use
antibody-coated magnetic beads or microfluidics that target proteins of interest such as
exosome-specific tetraspanins [20,21].
Commercially available kits have been recently developed to facilitate exosome isola-
tion with faster and simpler methods. Two of these kits are ExoTEST™ (Galen Laboratory
Supplies, North Haven, CT, USA), an ELISA-based assay for quantitative and qualitative
analysis of exosomes [22], and ExoQuick® (SBI System Biosciences, Palo Alto, CA, USA), a
proprietary polymer that gently precipitates exosomes and microvesicles [35].
2.3. Circulating Tumor Cells (CTCs)
CTCs are released from primary tumors and their metastases into the bloodstream and
great advances have been made to achieve an efficient capture of these cells from whole
blood. Current technologies include two main steps: CTC detection and CTC enrichment,
and the techniques available are based on different methods that target either physical or
biological/immunological characteristics of CTCs.
Immunoaffinity enrichment methods use specific antigens that are expressed on the
surface of CTCs. When tumor cells are captured, the technique is classified as positive
enrichment and epithelial cell adhesion molecule (EpCAM) and cytokeratin are the most
common targets. When the target is an antigen that is not expressed on CTCs the technique
is classified as negative enrichment, and CD45 is usually targeted for eliminating contami-
nating white blood cells [20,24]. These techniques are very specific, but a main drawback
is that only one subpopulation of tumor cells can be captured, and tumor heterogeneity
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may not be represented unless multiple antibodies are employed. Also, recovering cells
from the surface of the device may be difficult and cells can be damaged, a problem that is
solved when using immunomagnetic strategies [36].
CellSearch® (Menarini Silicon Biosystems Inc., Huntington Valley, PA, USA) is the
current gold standard and the only US Food and Drug Administration-approved plat-
form and uses magnetic beads covered with anti-EpCAM, anti-cytokeratin, and anti-CD45
to recover CTCs [20]. MACS® (Miltenyi Biotec, Bergisch Gladbach, Germany) [37] and
MagSweeper [38] are other platforms that use EpCAM-based markers, while AdnaTest and
Strep-tag® (Ibian Technologies, Zaragoza, Spain) use a cocktail of antibodies against multi-
ple antigens (EpCAM, EGFR, and HER2) with a high capture efficiency and purity [24,39].
Other epithelial cells that have similar characteristics as epithelial CTCs may result in
false-positive results and therefore epithelial-to-mesenchymal transition (EMT) and stem
cell markers should also be considered [36].
Negative enrichment-based platforms using anti-CD45 antibodies are MACS®, Quadrupole
Magnetic Sorter (QMS) [40], Dynabeads® (Invitrogen, Carlsbad, CA, USA), and EasySep™
(Stemcell Technologies, Vancouver, Canada) [24]. These methods capture CTCs with a lower
purity than positive enrichment methods, however, the advantage of negative enrichment
methods is that label-free CTCs can be obtained [36].
Other immunocapture platforms that use positive enrichment affinity-based tech-
nologies are based on microfluidic devices such as CTC-chip [41], herringbone chip [42],
high-throughput micro sampling unit (HTMSU) [43] and geometrically enhanced differ-
ential immunocapture (GEDI) chip [44]. These devices offer advantages for CTC research
such as improved capture efficiency and high purity [24].
Physical methods rely on biophysical properties, mainly size and density. These
methods are independent of antigen expression on the surface of a cell and better represent
the tumor heterogeneity than antigen-based methods. Also, these methods are faster
and simpler, they are less expensive and result in label-free, unmodified and viable cells,
enabling subsequent downstream methods. However, these isolation methods must be
followed with immunohistochemistry, immunocytochemistry, or immunofluorescence
labelling to distinguish CTCs from other cell populations [20,36].
Size-based separation isolates CTCs depending on their increased size (9–19µm).
These methods mainly use membrane microfilters, with platforms as ISET® (Rarecells
Diagnostics, Paris, France) and ScreenCell® (Sarcelles, France) and microfluidic sorting
devices such as ApoStream® (Precision for Medicine, Bethesda, MD, USA) and DEPArray™
(Menarini Silicon Biosystems), that use dielectrophoresis to separate CTCs [45,46]. Other
microfluidic chips such as CTC-iChip and NanoVelcro, combine size and affinity to separate
CTCs with higher purity and specificity [20,47,48].
Density-based methods use the specific density of red blood cells, leukocytes, and
cancer cells to isolate CTCs by centrifugation gradients. Platforms that use this technology
include OncoQuick® (GrenierBioOne, Frickenhausen, Germany) and AccuCyte® (RareCyte
Inc., Seattle, WA, USA) [49,50], and can obtain recovery rates of 90% [36].
2.4. Cell-Free RNAs (cfRNAs)
RNA molecules have also been detected body fluids. Most studies are focused on non-
coding RNAs, mainly microRNAs (miRNAs) and long non coding RNAs (lncRNAs). These
RNAs are released by different cell components of the tumor and its microenvironment, mostly
packed into exosomes or associated with protein complexes that prevent their degradation
by RNases [57,58]. MiRNAs are short (19–23 nt), single-stranded non-coding RNAs, while
lncRNAs are non-protein-coding transcripts with a length of more than 200 nt. They are both
involved in the regulation of gene expression at the post-transcriptional level [59].
Sample quality and processing are important factors affecting the quality and quantity
of cfRNAs. Pre-analytical and analytical aspects should be considered since physiological
processes such as blood hemolysis of blood during plasma collection can influence the
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measurement of cfRNAs [60,61]. The methods used for the isolation of exosomes also can
also affect the quality of exosomal miRNA profiles [51].
Many specialized kits for miRNAs isolation and a range of sample types, including
serum and plasma, are commercially available and may be used with small sample vol-
umes. lncRNAs can be isolated with regular RNA organic extraction methods [60,62,63].
Measurement and quantification of isolated RNAs rely on fluorometric methods such
as Qubit, more sensitive and with a greater tolerance for the presence of contaminants
than NanoDrop (spectrophotometry-based method), or Bioanalyzer (microfluidics-based
automated electrophoresis) [60].
Methods for the evaluation of cfRNAs include sequencing and RT-qPCR. The main
problem in cfRNA isolation from exosomes is their low concentration, which can be ad-
dressed with more sensitive techniques such as ddPCR [51]. Recently, PCR-free techniques
have been developed such as electrochemical approaches [64] or thermophoretic sensors
implemented with nanoflares for in situ detection of exosomal miRNAs [51,65].
2.5. Tumor Educated Platelets (TEPs)
It is now known that platelets can regulate tumor progression and metastasis as well as
response to chemotherapy [66,67]. In the interaction between the tumor microenvironment
and platelets, platelets uptake tumor proteins, extracellular vesicles and mRNA resulting in
their education, and TEPs can then reflect the tumor-of-origin profile [22]. This interaction
affects the expression of relevant genes in tumour cells and alters the RNA profile of the
TEPs [68]. Studies have also shown that platelet number and size can provide information
about the presence of cancer [69].
Platelets are a very abundant population in blood, so their isolation is relatively
simple with a two-step centrifugation protocol. Whole blood can be stored for up to 48 h at
room temperature prior to platelet isolation while maintaining high-quality RNA [22]. For
their analysis, the thromboSeq platform has been developed, an RNA-sequencing-based
methodology that enables identification of spliced RNA profiles from small amounts of
platelet RNA [70].
3. Liquid Biopsy in Other Body Fluids for the Early Detection of PDAC
Molecular analyses for the early detection of PDAC via LB are also being developed in
other body fluids such as pancreatic juice, saliva and urine. The collection of pancreatic juice
from the duodenal lumen is less invasive than other tissue biopsy collection methods, but it
is still a relative invasive and difficult technique that needs to be performed by specialized
personnel. Nevertheless, a number of molecular studies have been performed for the diag-
nosis of PDAC using pancreatic juice, mainly for the detection of KRAS mutations [71]. A
meta-analysis of 16 studies that analyzed the diagnostic value of KRAS mutations revealed
that the sensitivity and specificity levels for the diagnosis of PDAC were 0.59 and 0.87, re-
spectively [72], and another meta-analysis of 39 studies assessing the diagnostic value of the
four major altered genes in PDAC (KRAS, CDKN2A, TP53 and SMAD4), telomerase activity,
and combination assay revealed that the most reliable marker was telomerase activity with a
sensitivity and specificity of 0.82 and 0.96, respectively [73]. However, these results should be
analyzed with caution since they cannot distinguish early PDAC from intraductal papillary
mucinous neoplasm (IPMN), or pancreas with low-grade PanIN, since alterations of KRAS
and telomerase activity are also found in these lesions [71].
Saliva is a very convenient fluid for LB determinations since it can be easily and
noninvasively obtained from patients, and it has been reported that it contains almost
the same molecules as serum because of the high blood flow in salivary glands [25].
Molecular studies have been performed in saliva for the diagnosis of PDAC. Exosomes
have been found in saliva in preclinical models and have been reported to discriminate
PDAC, hence, they might be potential biomarkers for detecting PDAC [74]. A salivary
transcriptomic analysis has identified a four-messenger RNA panel (MBD3L2, KRAS,
ACRV1 and DPM1) that discriminates patients with PDAC from healthy controls with 0.9
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sensitivity and 0.95 specificity [75]. MiRNAs miR-3679-5p and miR-940 have been reported
to be down- and up-regulated in PDAC compared to healthy controls and benign lesions.
The combined analysis of these miRNAs showed 0.7 sensitivity and 0.7 specificity in PDAC
vs. noncancer [76]. The same group evaluated the expression of salivary lncRNAs and
identified up-regulated levels of HOTAIR and PV1T in PDAC patients in comparison to
healthy controls, with a combined sensitivity and specificity of 0.78 and 0.91 respectively.
These values raised to 0.82 sensitivity and 0.95 specificity when differentiating PDAC from
benign tumors [77].
Urine can be viewed as an ultrafiltrate of plasma and therefore may contain biomarkers
that could assist with PDAC diagnosis [25]. Urine LB has the main advantages of allowing
a completely non-invasive sampling and high volume collection, and has a lower proteome
content than blood to avoid contamination of possible biomarkers [78]. Because of this,
many metabolomic [79–82] and proteomic [83–86] studies have been conducted in order
to identify possible biomarkers that can aid in the early identification of PDAC. With this
purpose, Debernardi et al. have reported a urinary biomarker panel comprising LYVE1,
REG1B, and TFF1 and PancRISK score that can discriminate patients with early stages of
PDAC from control individuals and patients with benign hepatobiliary diseases [87].
Regarding cell free nucleic acids, detection of KRAS mutations in urine from PDAC
patients has also been reported, and the detection rate and sensitivity are comparable
to plasma LB [88]. Urinary miRNA biomarkers have also been analyzed and significant
over-expression of miRNAs in PDAC Stage I versus healthy individuals (miR-143, miR-223,
miR-30e) and Stage I versus Stages II-IV PDAC (miR-204, miR-143, miR-223) have been
described [89]. A recent study also showed that the miR-3940-5p/miR-8069 ratio in urine
exosomes is elevated in PDAC patients, suggesting that it may be a potential diagnostic
tool for PDAC, especially in combination with CA19.9 [90].
4. Early Detection of PDAC
The only curative treatment for PDAC is surgery, and this is only possible when the
tumor is diagnosed in early stages. However, in this phase of the disease, PDAC is usually
a silent tumor and only in 10–20% of patients is it possible to make the diagnosis in early
stages [91]. Currently we do not have sufficiently sensitive and specific tests to be used in
the clinical practice, so no strategy has been established for early diagnosis in this tumor [92].
However, the 5-year survival of patients diagnosed in initial stages is 20%, while when there
are metastases, it is only 3%, so it would be essential to have effective screening tests that
allow increasing the proportion of patients diagnosed in early stages in order to improve
survival. LB, in its different modalities, is being actively investigated in this field.
4.1. ctDNA
ctDNA represents less than 1% of all cfDNA. Its half-life is very short, since it is
degraded by nucleases and eliminated through the urinary tract. Its concentration depends
on the tumor volume, being detected more frequently in advanced tumors than in the early
stages. All this makes its detection in early stages a technological challenge [93].
Mutations in KRAS represent the earliest genetic alteration driving PDAC and are
found in over 90% of PDACs. It is possible to detect them in ctDNA, CTCs and exosomal
DNA (exoDNA) [21], so their identification by LB could be very useful in the early diagnosis
of PDAC. However, various studies have reported that the possibility of detecting ctDNA
in patients with early stages is 30–65% [94–97] and 70–80% for locally advanced and
metastatic PDACs [21] (Table 2).
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Table 2. Potential liquid-biopsy clinical usefulness in early-diagnosis of pancreatic cancer.
Study Technique Specific/Relevant Molecular Findings Stage Nº PatientsPDAC/Control Sensitivity (%) Specificity (%) Ref.
ctDNA ctDNA







Mutations at codons 12, 13 and 61 of KRAS Early PDAC 112 62 NR [95]
Mutations KRAS exon 2 (codons 12 and 13) All stages 52/10 65 75 [94]
KRAS MAFs All stages 110/52 47 NR [96]
Mutations at codons 12, 13 of KRAS Early PDAC 221/182 30 NR [98]
Mutations at codons 12, 13 and 61 of KRAS Early PDAC 112/76 71 NR [99]
ctDNA combined with other
serum tumor markers
ctDNA+ CA19.9 Mutations KRAS exon 2 All stages 47/31 85-98 77-81 [100]
ctDNA+ CA19.9 KRAS MAFs All stages 110/52 47 [96]
KRAS ctDNA + CEA + CA19.9 + HGF
+ osteopontin Mutations at codons 12, 13 of KRAS Early PDAC 221/182 64 99 [98]
cfDNA methylome 5-methylcytosine and5-hydroxymethylcytosine Global DNA hypomethylation All stages 72/136 94 95 [101]
CTCs





CD45/CEP8/DAPI staining-FISH CTC detection PDAC 95/48 76 68 [103]







Combined analysis CTC + exosomes CTC detection and GPC1-positive-exosome detection Early PDAC 22/28 100 80 [105]
Exosomes















GPC1-exosomes CTC detection and GPC1-positive-exosome detection Early PDAC 22/28 50 90 [105]
miRNAs of exosomes miRNAs in exosomes All stages Reported increasedexpression in PDAC NR [107–110]
miRNAs
miR-21, miR-25 miR-21, miR-25 All stages 303/760 75 93 [111]
Meta-analysis Presence of different miRNAs All stages 4,326/4,277 79 74 [112]
ctDNA: circulating tumor DNA; PDAC: pancreatic ductal adenocarcinoma; NR: not reported, CTC: circulating tumor cells; miRNA: micro-RNA; HGF: hepatocyte-growth factor; CEP8: chromosome 8 centromere;
FISH: fluorescence in situ hybridization; IPMN: intraductal papillary mucinous neoplasm; EpCAM:epithelial cell adhesion molecule.
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A recent meta-analysis that included seven studies that evaluated the role of ctDNA
in the diagnosis of PDAC found a pooled sensitivity of only 0.64 [113]. This relatively low
sensitivity is attributed to the fact that in early PDAC the rate of necrosis and apoptosis is
lower and not enough ctDNA is released into the peripheral blood [114]. In fact, it has been
pointed out that in the initial stages of PDAC, only one ctDNA molecule can be detected for
every 5 mL of plasma [113]. This represents a challenge that can be resolved as technology
improves.
It has been recently reported that with dPCR techniques it is possible to detect KRAS
mutations in up to 71% of patients with localized PDAC [99]. However, there is a risk that
increasing the sensitivity of the technique may decrease its specificity. In fact, it has been
suggested that it is possible to detect KRAS mutations in 7.4% of exoDNA and 14.8% of
cfDNA in healthy controls [106], and in 20% of patients with chronic pancreatitis [115], and
these numbers may increase as the sensitivity of the technique increases. It is unknown
whether these positives may correspond to pancreatic pre-malignant processes or extra
pancreatic KRAS-mutated tumors, and the possibility that driver mutations accumulate
with aging has also been suggested [116].
It is also of interest to quantify ctDNA by determining the MAF. In fact, the MAF of
KRAS in ctDNA is different in patients with pancreatic cysts, chronic pancreatitis, benign
tumors, localized, locally advanced and metastatic PDAC [96,97,117].
The possibility of using ctDNA together with other biomarkers that could improve the
sensitivity and specificity of LB in screening has been investigated. Thus, for example, the
combination of KRAS mutations and CA19.9 showed a sensitivity of 0.98 and a specificity
of 0.77 to differentiate PDAC from chronic pancreatitis [100]. Likewise, this combination
of markers shows a sensitivity of 0.82 and a specificity of 0.81 to differentiate between
PDAC and benign pancreatic tumors [96]. It has also been suggested that the combination
of ctDNA with certain plasma proteins could improve the reliability of the test. In fact, in
a study it was reported that the use of KRAS mutation in ctDNA allowed the detection
of 30% of the cases, but the combination of KRAS mutation in ctDNA with four protein
biomarkers (CEA, CA19.9, hepatocyte growth factor and osteopontin) achieved to detect
64% of patients. Furthermore, only 1/182 healthy controls were positive, giving a specificity
of 0.99 [98]. This strategy is very promising for PDAC screening, although it needs to be
validated in large population studies.
It has recently been suggested that epigenetic alterations -which are tissue- and cancer-
type specific-potentially have a greater ability to detect and classify cancers in patients
with early-stage disease. In a study that included several tumors, it was found that the
analysis of cfDNA methylome allowed their early diagnosis [52]. In a pilot study it was
reported that a model combining the modifications in 5-methylcytosine (5mC) and 5-
hydroxymethylcytosine (5hmC) in cfDNA achieved a sensitivity of 0.94 and a specificity of
0.95, with an AUC of 0.99 for the diagnosis of PDAC [101].
A prospective case-control sub-study (from NCT02889978 and NCT03085888) assessed
the performance of targeted methylation analysis of circulating cell-free DNA (cfDNA) to
detect and localize multiple cancer types across all stages. 2482 cancer patients with more
than 50 cancer types and 4207 non-cancer patients were included. Among the 84 patients
included with PDAC in different stages, a sensitivity of 0.63 in stage I, 0.83 in stage II, 0.75
in stage III, and 1.0 in stage IV was found [118]. All these results suggest that the analysis
of epigenetic modifications of cfDNA may be a very promising tool for the early diagnosis
of PDAC.
4.2. Exosomes
Pancreatic cells have a strong exocrine function, which favors the continuous release of
exosomes into the bloodstream. Furthermore, the half-life of exosomes is longer than that of
ctDNA, so its detection does not depend on the occurrence of apoptosis or necrosis. These
characteristics make them very interesting tools for early diagnosis [106]. Furthermore,
exosomes carry the physiopathological signature of the cells from which they originate,
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both in membrane molecules and in the content of the vesicles [119]. For this reason, the
analysis of their genetic material and that of their proteins can help in the early diagnosis
of PDAC.
Although it was initially suggested that the presence of heparan sulfate proteoglycan
glypican-1 (GPC1) could be detected in the exosome membrane of 100% of PDAC patients,
and therefore could be used for the differential diagnosis with benign lesions [120], further
studies found GPC1 in a much lower percentage, so that it did not allow its use for the
diagnosis of PDAC [107].
Various authors have focused on the study of KRAS mutations in exoDNA. In a study
that compared the performance of the determination of KRAS mutations in exoDNA and
ctDNA, it was observed that they could be detected respectively in 66.7% and 45.5% of
patients with localized PDAC, in 80% and 31% of locally advanced patients and in 85%
and 58% of metastatic patients. However, these results could not be reproduced in the
validation cohort, where it was only possible to find mutant KRAS exoDNA in 44% of
early-stage PDAC patients [106].
Other studies have focused on the miRNAs of exosomes and have detected that PDAC
patients present an increased expression of miR-17-5p and miR-21, which does not occur
in healthy controls [108]. In another study, miRNAs miR-10b and miR-30c were found to
be elevated and associated with the diagnosis of PDAC [107,109]. In addition, exosomal
miRNAs would make it possible to differentiate pancreatitis from PDAC [107].
It has been reported that in the exosomes of patients with PDAC the pancreatic cancer-
initiating cell protein CD44v6, tetraspanin-8, EpCAM and CD104 are increased and the
miRNAs miR-1246, miR-4644, miR-3976 and miR-4306 are overexpressed, while this does
not occur in healthy controls, which opens the possibility of using these molecules as
biomarkers for early diagnosis [110].
4.3. CTCs
CTCs are tumor cells that invade blood vessels during the metastasis process. They
can be found as isolated cells or as cell clusters forming a tumor microthrombus. Various
studies have indicated that CTCs can be detected in 21–100% of patients with PDAC,
depending on the series, stage, and technique used [113,121,122]. However, compared to
other epithelial tumors, fewer CTCs are detected in PDAC and in fewer patients, so the
sensitivity of this technique for early diagnosis is low.
Despite its variable sensitivity, its specificity is very high, since they are hardly found
in healthy controls. In a study with early-stage tumors, CTCs could be found in 75–80%
of patients [123,124], but other studies have reported detection rates below 50% [102].
Furthermore, it has been reported that it was possible to find circulating epithelial cells
(CECs) in 33% of patients with intraductal papillary mucinous neoplasm (IPMN) without
PDAC, and in 73% of PDACs [102]. Similarly, in another study the same proportion of
CECs was detected in patients with benign, premalignant, and malignant lesions, although
they were not found in healthy controls [125].
In a meta-analysis that included 19 studies with a total of 1872 patients, it was observed
that the sensitivity, specificity and AUC for the diagnosis of PDAC when using ctDNA
were 0.64, 0.92 and 0.94, if exosomes were used they were 0.93, 0.92 and 0.98 and if the
CTCs were studied they were 0.74, 0.83 and 0.81 respectively [113]. This lower AUC of
CTCs compared to other LB modalities can be attributed to the fact that CTCs can become
trapped in the liver when they travel through the portal vein, and because, compared to
normal pancreatic tissue, the blood flow within the pancreatic tumor tissue is reduced by
60% [113]. In fact, it has been pointed out that when blood from the portal vein is analyzed,
the ability to detect CTCs notably increases, therefore, they can be found in 100% of patients
with metastatic PDAC [126] and in 58% of resectable patients [104]. The problem is that
this type of procedure increases the invasiveness and complexity of the technique.
The ability to detect CTCs not only depends on the stage of the PDAC, but also on the
technology used. A recent study suggests that combining the determination of CTCs by
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two different procedures (RosetteSepTM and CellSearch® (Menarini Silicon Biosystems))
together with the determination of positive GPC1 exosomes increases the sensitivity of the
procedure up to 100%, although with a specificity of 80%, since they could identify CTCs
in 50% of the IPMN and in 10% of the healthy controls [105] (Table 2).
4.4. cfRNAs
The possible role of plasma miRNAs for the early diagnosis of PDAC has also been
investigated. Various miRNAs that could be used as biomarkers in this scenario have been
identified, among which miR-21 and miR-25 stand out. The results of a meta-analysis
showed that miR-21 would have a sensitivity for early diagnosis of 0.90 and a specificity of
0.72 [127]. In another study miR-25 was also reported to have a high capacity for PDAC
diagnosis with a sensitivity of 0.75 and 0.93 specificity [111].
On the other hand, it has been suggested that the combination of several miRNAs
could improve the diagnostic capacity. It has recently been proposed that a signature
made up of 13 miRNAs would make it possible to distinguish PDAC patients from healthy
subjects [128].
Circulating miRNAs can also aid in the differential diagnosis between benign and
malignant IPMN. It has been reported that miR-233 is not only elevated in the plasma of
patients diagnosed with PDAC, but is also found in higher levels in malignant than benign
IPMN [129]. Likewise, miR-196a and miR-196b are higher in patients with PanIN2-3 than
in patients with PanIN-1 [130].
In patients at high risk of developing PDAC or with a history of familial pancreatic
cancer, it was observed that a panel composed of miR-196b, LCN2 and TIMP1 allowed the
differentiation of high-grade lesions and stage I PDACs from healthy controls [131].
A recent meta-analysis, which included a total of 46 studies, 4326 PDAC patients and
4277 non-PDAC controls, reported that miRNAs offered a cumulative sensitivity for the
diagnosis of early stage PDAC of 0.79 and a specificity of 0.74. Furthermore, they found
that the combination of miRNAs and CA19.9 could improve these figures [112].
We can conclude by stating that the studies carried out for the early diagnosis of
PDAC with LB are promising, although the sensitivity and specificity of the different
techniques must be improved. Probably the combination of some of them together with
certain biomarkers will improve their reliability. In any case, before it can be applied
in healthcare practice, it is necessary to verify its performance in clinical trials with an
adequate number of patients. Ongoing clinical trials that use LB in PDAC are shown in
Table 3.
lncRNAs are also involved in cellular processes in PDAC, such as cell proliferation,
epithelial-mesenchymal transition (EMT) and metabolic reprogramming [132]. Abnormal
expression of lncRNAs has also been identified in pancreatic cancer and may be involved in
cell growth, apoptosis, invasion, metastasis and angiogenesis [25]. Promising results have
been reported in pre-clinical studies that point at these molecules as possible diagnostic
and prognostic biomarkers.
The expression levels of lncRNA SNHG15 were studied in a series of 171 PDAC
patients, and the results showed that SNHG15 was upregulated in PDAC tissue and serum
samples compared with paracancerous tissue and healthy controls, so, SNHG15 may be
a potential biomarker for differentiating PDAC tissues from normal pancreatic tissues.
Clinicopathologic analysis revealed that high SNHG15 expression was associated with
tumor differentiation, lymph node metastasis and tumor stage (p < 0.005), and patients with
high SNHG15 expression had a shorter OS compared with the low SNHG15 expression
group (p = 0.003). Also, Cox multivariate analyses confirmed that SNHG15 expression was
an independent prognostic factor in PDAC (p < 0.004) [63].
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Table 3. Liquid biopsy in pancreatic cancer ongoing clinical trials.
Trial Trial Design Trial Purpose Study Population n Primary Endpoint Technique Ref.
DYNAMIC-Pancreas: ctDNA
Analysis Informing Adjuvant
Chemotherapy in Early Stage PDAC:





408 DFS ctDNA ACTRN12618000335291
Mutation of KRAS, CDKN2A,
SMAD4 and TP53 in PDAC















and TP53 mutation on
circulating cfDNA
NCT03524677
Prognostic Role of ctDNA in
Resectable PDAC (PROJECTION)
Comparison of DFS of
patients with
preoperative presence
of ctDNA (Group A)
and absence of ctDNA
(Group B)
Diagnostic
Prognostic Resectable PDAC 200
To determine the stage,
the remission or the
progression of PDAC
Collected prior of surgery




Detection of High Expression Levels
of EMT-Transcription Factor mRNAs












mRNA levels in blood
NCT04323917
Verification of Predictive Biomarkers
for PDAC Treatment Using
Multicenter Liquid Biopsy
Observational Diagnostic Subjects affected by PDAC 662 Clinical applicability
1-Quantification and
monitoring of KRAS






Small RNA as Potential Biomarker
for Human PDAC
Cohort-prospective DiagnosticEarly-detection






Diagnostic Accuracy of CTCs and
Onco-exosome Quantification in the
Diagnosis of PDAC-PANC-CTC
(PANC-CTC)
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Table 3. Cont.
Trial Trial Design Trial Purpose Study Population n Primary Endpoint Technique Ref.
PRIMUS002: Looking at 2
Neo-adjuvant Treatment Regimens








278 Time to progression ctDNA NCT04176952
Tumor Markers, Liquid Biopsies,
and Patient Reported Outcomes in
Metastatic Colorectal, Pancreas,
Biliary, and Esophagogastric Cancers
Observational









































1250 Sensitivity for earlydiagnosis cfDNA NCT03568630
Nalirinox Neo-pancreas RAS Mut




20 Monitoring response KRAS ctDNA NCT04010552
ctDNA: circulating tumor DNA; cfDNA: cell free DNA; cRNAs: circular RNAs; PDAC: pancreatic ductal adenocarcinoma; DFS: disease-free survival; CTCs: circulating tumor cells; EMT: epithelial-mesenchymal
transition.
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Other lncRNAs such as POU6F2-AS2 or extracellular vesicle-encapsulated HULC
have been found in higher levels in the sera of patients with PDAC than in healthy controls
and could be explored as potential biomarkers for human PDAC [133,134].
Yu et al. have developed a d-signature with eight long RNAs from plasma extracellular
vesicles for PDAC detection in a study that enrolled 501 patients. This d-signature is able to
identify resectable stage I/II cancer with an AUC of 0.949 and shows a better performance
to CA19.9 in distinguishing PDAC from chronic pancreatitis (AUC 0.931 vs. 0.873, p =
0.028) [62].
4.5. Liquid Biopsy in the Diagnosis of PDAC
Currently, the diagnosis of PDAC is made by imaging tests and obtaining tumor
samples, usually by ultrasound-guided fine needle aspiration (US-FNA). This test is inva-
sive, and either due to technical difficulties or due to the important stromal component
of the tumor, tumor cells are sometimes not obtained to confirm the diagnosis, even after
repeating the test. In these cases, surgery is necessary to obtain a tumor sample. In this
context, LB could help confirm the diagnosis without subjecting the patient to the risks of
aggressive testing. However, the performance of LB varies with the tumor stage, so that in
patients with resectable disease, ctDNA is detected less frequently than in patients with
unresectable disease and, in addition, they present fewer genomic alterations [129].
A study that compared the diagnostic value of CTCs, ctDNA and CA19.9, showed
that while the sensitivity and specificity for PDAC diagnosis for US-FNA were 0.73 and
0.88, for ctDNA were 0.65 and 0.75, for CTCs were 0.67 and 0.80, and 0.79 and 0.93 for
CA19.9, respectively. In patients with positivity for two of these biomarkers, sensitivity
and specificity improved, reaching 0.78 and 0.91, respectively [94]. A recent meta-analysis
demonstrated that in patients with advanced disease, the sensitivity and specificity for
PDAC diagnosis of ctDNA were 0.64 and 0.92, for exosomes 0.93 and 0.92, and for CTCs
0.74 and 0.96, respectively [113].
5. Detection of Recurrence
In PDAC patients, recurrences after surgery are very frequent. In resectable PDAC
they are detected in up to 60% of patients during the three years following surgery [7],
and in borderline cases in 80% of patients in the first year after the surgical process [135].
The conventional prognostic factors of PDAC are usually tumor size, lymph node status,
perineural invasion, and resection margin, but they have the disadvantage that they can
only be obtained after surgery. However, various evidences suggest that LB can offer
prognostic information from the moment of diagnosis, but also during follow-up and
tumor progression. After completing surgical treatment and adjuvant treatment, a follow-
up program is usually started that includes serial assessment using CT imaging and CA19.9
testing. However, various meta-analyses indicate that CT and CA19.9 only have moderate
diagnostic accuracy for the diagnosis of recurrent PDAC [136,137]. It should also be noted
that CA19.9 is limited by its low sensitivity and that 5–7% of patients have Lewis-negative
genotypes and, therefore, are unable to produce CA19.9 [138]. In this context, the possible
role of the different LB modalities to detect recurrence is being investigated.
5.1. ctDNA
Since the half-life of ctDNA is very short, after complete removal of the tumor, no
ctDNA should be detected. However, its persistence after surgery indicates that the disease
has probably remained and, therefore, there is a high risk of recurrence.
Various studies have indicated that the determination of KRAS mutated ctDNA during
follow-up after surgery has a sensitivity and specificity of around 0.90 to predict recurrence,
anticipating its detection by imaging techniques by several months [135,139]. After surgery,
it is possible to detect ctDNA in 30–45% of patients [95,139], and in these cases, the relapse
rate is very high, reaching 100% in some series [95]. In addition, the median Relapse Free
Survival (RFS) ranges from 5–10 months. These data suggest that in patients in whom
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ctDNA is detected after surgery, adjuvant treatment should be administered and ctDNA
levels should be monitored, since its elevation during treatment could be an indicator that
resistance has developed and, therefore, modification of treatment should be considered.
Likewise, the detection of KRAS mutated ctDNA before surgery implies a poor prog-
nosis, so that it predicts both decreased median RFS (6 vs. 16 months; p < 0.001) and
decreased OS (14 vs. 28 months; p < 0.0001) [140]. In one study, which included patients
with resectable PDAC, KRAS mutated ctDNA was detected in 62% of patients before
surgery, and it was associated with significantly lower RFS and OS. In fact, 83% of patients
with detectable ctDNA at diagnosis relapsed [95]. These data suggest that those patients
with resectable PDAC in whom ctDNA is detected before surgery are a high-risk group
in which neoadjuvant therapy strategies could be explored. When ctDNA was detected
at diagnosis and became negative after surgery, the risk of relapse was lower than when
ctDNA levels remained high [95].
In addition to the detection of ctDNA, it has been pointed out that its quantification
also has prognostic importance, since patients with an elevated MAF prior to surgery have
a higher risk of relapse and a lower DFS [99].
5.2. Exosomes
TDEs may reflect the response to surgery, such that their persistence after resection is
related to the presence of hidden metastases. Patients with more than 20% GPC1 positive
exosomes in peripheral blood have been reported to have lower progression-free survival
(PFS) and OS [105]. Similarly, the detection of high exosome-encapsulated miR-415a
was also associated with worse PFS or OS [141]. Furthermore, the detection of exosome-
encapsulated miR-4525, miR-415a, and miR-21 in the portal vein was more sensitive in
identifying patients at high risk of recurrence after surgery than its detection in peripheral
blood [142].
5.3. CTCs
In patients with resectable PDAC, it is possible to detect CTCs in percentages ranging
between 5 and 60% of cases depending on the technique used [143–145]. The detection rate
with CellSearch® has been reported to be 26% (95% CI: 14–38%), which is lower than the
figures obtained with filtration or microfluidic techniques. In addition, the detection rate is
significantly increased when blood from the portal vein is analyzed compared to peripheral
blood [146]. It has been reported that 85% of patients with CTCs in the portal circulation
developed liver metastases, while this only occurred in 13% of patients in whom they were
not detected [104].
Both preoperative chemotherapy and surgery achieve a significant reduction in CTCs,
but not their complete disappearance. In the three days following surgery, a decrease in
CTCs is observed, and their subsequent increase may indicate the existence of metastatic
disease [121]. Recurrences have been observed to occur more frequently in patients in
whom CTCs are detected than in those in whom they are not [147].
In addition to the presence and number of CTCs, the type of CTC is also of prognostic
importance [144]. Two subtypes of CTCs have been identified in PDAC patients: epithelial
and epithelial/ mesenchymal, so that the detection of CTCs with positive stain for cytok-
eratin (epithelial marker) is associated with worse survival than if CTCs are positively
stained with vimentin (mesenchymal marker) [144]. Furthermore, the detection of CTCs
that co-express cytokeratin and vimentin is associated with a shorter relapse-free time [147].
Likewise, the detection of a tumor initiating cell (TIC) phenotype (evaluated with the
expression of aldehyde dehydrogenase, CD133, and CD44) was associated with tumor
recurrence and decreased DFS [145]. In another study, it was reported that the detection of
cancer stem cells expressing ALCAM, CD44, and POU5F1B was related to more aggressive
tumors and a worse prognosis [148,149].
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5.4. miRNAs
In surgical patients, elevated levels of miR-744 and downregulated levels of miR-373-
3p are associated with a poor prognosis, the appearance of recurrences and the development
of metastases, and resistance to chemotherapy [150]. Increased expression of miR-18a has
also been related to recurrence after surgery, and this elevation may be independent of the
CA19.9 level. The same occurs with the elevation of miR-21-5p [151]. On the contrary, the
decrease in miR-196a, miR-196b, miR-221 and miR-483 after surgery would be related to a
favorable prognosis [152,153].
The results of these studies suggest that LB in its different modalities can help in an
early detection of PDAC recurrence after surgery. A positive LB after surgery suggests
the presence of viable tumor tissue and, therefore, the necessary tests should be carried
out to locate the residual disease in case its eradication is possible or, alternatively, start
a treatment to delay the progression of the tumor. An unresolved question is whether
the possible clearance of ctDNA after adjuvant treatment implies an improvement in the
prognosis. This question is intended to be answered with the DYNAMICS-Pancreas clinical
trial that investigates the benefit of intensifying adjuvant treatment in those patients in
whom ctDNA continues to be detected after surgery (Table 3).
On the other hand, in patients with undetectable ctDNA after surgery it may be
considered not to administer adjuvant treatment. Unlike what occurs in other tumors such
as colon cancer, in PDAC the few data available suggest that these patients continue to
relapse in a significant percentage, although less than that of those with detectable ctDNA.
Alternatively, a less aggressive or shorter adjuvant treatment could be considered, but the
safety of these strategies needs to be demonstrated through prospective clinical trials.
6. Disease Monitoring
Current chemotherapy treatments have limited efficacy and yet can cause significant
toxicity. For this reason, it is important to rapidly identify patients who do not benefit
from treatment in order to suspend it and, if possible, start a new therapy. LB could help
in the early detection of response to treatment and tumor progression, and thus guide
treatment decisions. There are at least two situations where disease monitoring acquires
special relevance: in the context of neoadjuvant treatment and in metastatic disease. The
utility of LB has been investigated in both settings (Table 4).






Resectable 59 29 30 RFS 8mo if pre-surgery ctDNA + vs. 19mo if ctDNA- (p < 0.01) [135]
Resectable 37 23 14 RFS 10.3mo if pre-surgery ctDNA + vs. RFS not reached (p = 0.002) [95]
Resectable 34 14 * 20 * ExoDNA KRAS MAF peak of ≥1% after treatment is associated with tumor progression [97]
Advanced/metastatic 104 50 54 OS 6.5mo if ctDNA + vs. 19mo if ctDNA- (p < 0.001) [154]
Advanced/metastatic 55 42 13 OS 2.5mo if ctDNA + with copy number gain vs. 5.5mo without copy number gain vs.10.6mo if ctDNA- (p < 0.001) [155]
Metastatic 61 47 14 OS 5.6mo if ctDNA + vs. 12.4mo if ctDNA- (p < 0.001) [156]
Metastatic 102 70 32 OS 8.6mo if ctDNA + vs. 14.6mo if ctDNA- (p < 0.02)PFS 3.5mo if ctDNA + vs. 10.7mo if ctDNA- (p < 0.02) [97]
Any stage 77 60 17 KRAS MAF peak of <0.415% is associated with longer PFS and OS [157]
Advanced/metastatic 54 36 18 Decrease in KRAS ctDNA levels during chemotherapy (d14) is an early indicator ofresponse to treatment [158]
Metastatic 113 77 36 Early change in ctDNA levels (d28) was correlated with ORR, PFS and OS [159]
Advanced/metastatic 38 17 21 The dynamics of total cfDNA concentration correlated with tumor burden followingchemotherapy [117]
Metastatic 188 65 123 OS 4.7mo if ctDNA + vs. 6mo if ctDNA- (p = 0.015) [160]
ctDNA: circulating tumor DNA; MAF: mutant allele fraction; RFS: recurrence-free survival; OS: overall-survival; ORR: objective response
rate; * ExoDNA.
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6.1. Neoadyuvant Treatment.
One of the great challenges of oncology is the detection of minimal residual dis-
ease (MRD) after neoadjuvant treatment. Chemotherapy with or without radiotherapy
can achieve pathological complete response (pCR) in 3–11% of patients diagnosed with
PDAC [161]. In these cases, the prognosis notably improves, and as in other neoplasms, if it
were certain that the entire tumor had been completely reduced, it could be speculated on
the possibility of avoiding the inconveniences of a complex surgical procedure, which can
cause a high morbidity and even mortality. Likewise, it is of interest to monitor the disease
after surgery, in order to verify, in the event that MRD remains, that adjuvant treatment
manages to eliminate it.
Despite the better prognosis accomplished by achieving a pCR, more than half of the
patients will relapse after surgery. In fact, a study that analyzed the presence of ctDNA
and CTCs after surgery in patients who had achieved pCR after neoadjuvant treatment,
reported that it was possible to detect CTCs in 5 of 6 patients and ctDNA in 7 of 16 patients
with pCR. This led the authors to propose the concept of molecular complete response
(mCR) that would combine the study of the biopsy with the genomic analysis of the
resected tissue [162].
In a study that included 59 patients, of whom 30 underwent surgery directly and
20 received neoadjuvant treatment, ctDNA could be detected before surgery in 69% of
those who underwent surgery without prior neoadjuvant therapy compared to 21% of
patients who received neoadjuvant treatment. The presence of preoperative ctDNA was
associated with a significantly lower recurrence-free survival (RFS) and OS. In addition, all
the patients in whom ctDNA was still detected after neoadjuvant treatment relapsed, with
a median RFS of 5 months [135].
It has been proposed that monitoring of KRAS MAF in exoDNA during neoadjuvant
treatment can help predict PDAC resectability. In fact, in a study it was observed that
71% of patients in whom PDAC could be resected had a decreased KRAS MAF, while in
94% of patients whose PDAC was not resectable after neoadjuvant treatment, KRAS MAF
remained stable or increased [94]. Furthermore, the increase in exoDNA after neoadjuvant
treatment was significantly associated with disease progression [97].
6.2. Metastatic Disease
Various studies have shown that ctDNA can be detected in the plasma of 70% of
patients with metastatic PDAC, and that its presence is associated with a worse progno-
sis. Thus, for example, in a series of 104 patients, the median OS of patients in whom
ctDNA could be found was 6.5 months compared to 19 months in those without detectable
ctDNA [154]. The results of other studies have confirmed the negative prognosis of ctDNA
detection in patients with locally advanced or metastatic PDAC [97,155–157].
The presence of ctDNA, in addition to serving for prognosis, can be used as a
biomarker to monitor the response to treatment and indicate early resistance to it, so
that treatment can be modified depending on the evolution of the disease. In a study
with 54 patients with advanced PDAC undergoing chemotherapy, increased KRAS mutant
ctDNA predicted disease progression with a sensitivity of 83% and a specificity of 100%.
Furthermore, its decrease during treatment can predict its response [158]. In another study,
negative ctDNA during chemotherapy was associated with a higher PFS than in those
patients in which it was still detected [163], although this extreme could not be confirmed
by other authors [97]. In a phase II clinical trial conducted in patients treated with second
line chemotherapy, the prognostic and predictive value of ctDNA was investigated. 113
patients were included, and ctDNA was detected in 77% of them. It was observed that
patients with detectable ctDNA had worse PFS and OS, but also, an early change in ctDNA
levels was correlated with a higher response rate and a significant increase in PFS and
OS [159].
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In a study that included 13 patients with metastatic PDAC and studied the ctDNA
mutations of several genes such as KRAS, BRCA2, and EGFR, it was observed that new
mutations in ctDNA could be detected in patients progressing to chemotherapy [160].
PDAC has a large stromal component, so radiological images often do not adequately
reflect the response to treatment. In this situation, LB may also be helpful. In fact, the
previous study also investigated the concordance in the evaluation of the response by CT
and by ctDNA, and observed that although in 10 patients (77%) the result of the evaluation
coincided with the two techniques, in 60% of the cases ctDNA provided the earliest measure
of treatment [160].
The optimal time to perform the LB procedure is unknown. It has been observed that
7 days after starting treatment there may be elevations that lack prognostic significance,
but variations at 14 days may anticipate a radiological response [149].
Several authors have reported that the dynamic changes experienced by ctDNA during
treatment are not only related to the evolution of tumor volume, but also to PFS and OS, so
that it can serve as an early marker of response and as prognostic factor [117,158,161]. Fur-
thermore, increases in ctDNA MAF during treatment are associated with lower PFS [117].
Applying NGS techniques to the ctDNA of 188 patients with metastatic PDAC, mu-
tations in KRAS G12V and ERBB2 exon 17 were reported to be associated with reduced
survival. Furthermore, mutations in KRAS G12 were related to radiological responses [160].
On the other hand, it has been pointed out that higher methylation index values for SPARC
and NPTX2 genes in cfDNA were found to associate with poor survival in patients with
PDAC [164].
In patients with advanced PDAC, CTCs can be detected in a percentage that varies
depending on the technique used and the stage of the disease. Thus, for example, while
some authors found CTCs in 11% of patients with locally advanced PDAC [165], others,
using antibody-independent CTC isolation, have reported its detection in 77% of patients
with locally advanced stages and in 93% of stage IV [166]. Even with the use of the
CTC-Chip, its detection has been reported in 100% of patients [41].
In a meta-analysis that included nine studies with a total of 600 patients with any
stage PDAC, CTCs were identified in 43% of the patients, and it was observed that their
PFS and OS were significantly lower than those in which they could not be detected [167].
In addition to its prognostic value, the determination of CTCs during treatment can
guide the response to chemotherapy. It has been observed that after a chemotherapy
cycle with 5-FU, the percentage of patients in whom more than 2 CTCs could be detected
decreased from 80% to 29% [123]. In a study with 40 patients, dynamic changes in CTCs
were investigated during chemotherapy treatment, and CTCs were observed in 45% of
patients with progression or stable disease and only in 24% of those who achieved partial
response. Detection of CTCs was associated with a worse prognosis [168].
It has been reported that when the tumor progresses after chemotherapy, the CTCs
population also changes, with an enrichment in the CTCs of the expression levels of
stemness and pluripotency genes such as CD44, ALCAM, EPCAM, NOTCH1, POU5FIB,
and PTCH1, or CSC drivers as VEGFB and STAT3 [149]. Likewise, it has been proposed
that CTCs could serve to monitor the response to treatment, and indicate early resistance
to it [169]. Furthermore, it has been suggested that the pharmacogenomic study of RNA
extracted from CTCs could help predict the response to PDAC treatment and help optimize
treatment [170].
A study reported that the presence of MUC-1, a large trans-membrane glycoprotein
in the CTCs of PDAC patients was associated with a shorter OS than those with MUC-1
negative CTCs (2.7 vs. 9.6 months). Furthermore, the presence of anti-MUC-1 antibodies
was associated with longer survival [171]. In another study, the type of KRAS mutation
was found to have prognostic value, such that those with the KRAS G12V mutation had a
better prognosis than those with other or lacking KRAS mutations [172].
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7. Precision Medicine
ctDNA can provide clinicians with information on PDAC mutations and on the
epigenetic characteristics of the neoplasm [173,174]. There are important discrepancies
between the mutations detected in tumor and in plasma. In a study that included PDAC
and colorectal cancer patients and studied 56 genes by NGS in tumor tissue and in plasma,
it was observed that 78% of the mutations detected in plasma were not found in the
primary tumor [175]. In a recent meta-analysis, it was observed that considering studies
that analyzed KRAS mutations only, the concordance was 65%, but when considering all
mutations detected by multi-genes panels the concordance was only 31.9% [176].
These discrepancies can be attributed to the fact that the mutations present in the primary
tumor can be detected in the ctDNA, while in the analyzed tissue, due to tumor heterogeneity,
there may be mutations that are not detected [175]. On the other hand, the presence of
different clones in the metastases could also contribute to these discrepancies. In fact, some
studies have shown that driver gene mutations in PDAC are usually maintained during clonal
evolution [177,178], but throughout the progression of cancer, other molecular alterations are
added that are detectable in the metastases but not in the primary tumor [175,178].
LB describes in a more complex manner real time dynamics of tumor disease, provid-
ing complete information on the tumor genome, and enables the identification of changes
that occur during tumor treatment [174].
PDAC is associated with alterations in driver genes such as KRAS, CDKN2A, ERB2,
BRCA1/2, NTRK, etc., and these tumors are susceptible to targeted treatments. In a recent
retrospective study that included 1856 PDAC patients, 1082 (58%) received personalized
reports based on their molecular testing results, and actionable molecular alterations were
identified in 26% of the patients. Of these, 46 patients received matched therapy and had a
significantly higher OS than those who received unmatched therapies (2.58 years vs. 1.51
years, p < 0.0001) [179].
In another study, a potentially actionable mutation was detected in 29% of patients,
including ALK (ALK inhibitors), ATM (DNA cross-linking drugs or poly (ADP-ribose) poly-
merase inhibitors), DNMT3A (DNMT inhibitors), EGFR (EGFR inhibitors), KIT (KIT inhibitors),
MAP2K4 (MEK inhibitors), and PIK3CA (PI3K/AKT/mTOR) pathway inhibitors [180]. In an-
other study, a panel of 73 genes analyzed 357 samples from 282 patients with advanced PDAC.
After excluding variants of unknown significance, therapeutically relevant alterations were
observed in 170 (48%) samples. There were 40 patients in whom a ctDNA sample taken at
the time of diagnosis and progression was available, and it was observed that in 23 (57%),
ctDNA analysis allowed the detection of new genetic alterations at disease progression. None
of these newly acquired genetic alterations were identified on tissue profiling performed at
diagnosis [181].
These results highlight the importance of molecular studies in a tumor where the
therapeutic options are very limited and the finding of an actionable mutation represents a
great therapeutic opportunity. In addition, given that new genetic alterations may appear
with tumor progression, it is important to monitor these molecular changes throughout
the evolution of the disease. Given the difficulties that exist in obtaining a tumor sample
in PDAC, LB, due to its simplicity, accessibility, and the importance of the information it
can provide, should play a relevant role. In this sense, it should be noted that techniques
are being investigated to study the molecular profile and gene expression of CTCs, which
would allow us to know the gene expression changes that occur in tumor cells during
treatment and the possible development of resistance [182].
In any case, for the use of LB to spread in healthcare practice, it is necessary to define
the most appropriate technique, reduce costs, and have the results of prospective studies
that support the suitability of this tool.
8. Conclusions
Although there were many expectations set on the use of LB for early diagnosis, the
truth is that the relatively low sensitivity and specificity of current techniques does not
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allow its use for these purposes. In addition, the available studies suggest that patients
with PDAC in whom ctDNA is detected at the time of diagnosis have a poor prognosis
and have a high chance of relapse after surgery, so it is advisable to develop more sensitive
techniques that allow diagnosing tumors in earlier stages and provide patients with a
better prognosis. It is possible that, with the development of ultrasensitive techniques, the
joint use of different biomarkers and epigenetic marks, the sensitivity of LB will increase
without losing specificity, and LB could be applied in PDAC screening.
The different LB methods have been shown to be a reliable biomarker in relation to
the prognosis of patients with PDAC for both PFS and OS. Furthermore, its variations
throughout treatment predict response or resistance to treatment several weeks in advance,
so it could be used to guide treatment based on the evolution of the biomarker. In addition,
the study of the characteristics of CTCs, ctDNA, exoDNA and miRNA can help us to
better characterize the tumor and to identify potential therapeutic targets that facilitate the
selection of treatment.
However, it is necessary to standardize and validate the methodology to be used in
the different LB modalities. In addition, the usefulness of other LB modalities should be
explored, such as lncRNAs or TEPs. On the other hand, the usefulness of less invasive
sources of ctDNA such as urine or saliva needs to be further investigated.
Finally, it should be remembered that in order to apply LB to clinical practice, it is
necessary to reduce costs, standardize protocols, and have data generated in the context of
large-scale prospective clinical trials that confirm that the information provided contributes
significantly to improving therapeutic results in PDAC patients.
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